Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Editas Medicine's Renizgamglogene Autogedtemcel?
Renizgamglogene Autogedtemcel is a gene-modified cell therapy commercialized by Editas Medicine, with a leading Phase III program in Sickle Cell...
Data Insights
Risk adjusted net present value: What is the current valuation of Editas Medicine's Renizgamglogene Autogedtemcel?
Renizgamglogene Autogedtemcel is a gene-modified cell therapy commercialized by Editas Medicine, with a leading Phase III program in Sickle Cell...